Bora Pharmaceuticals

Activities: Manufacturing Research & Development Pharmaceutical

Trending Articles

  1. IMPACT CKD model reveals the escalating toll of chronic kidney disease The model projects up to 125 million of the population across eight countries to suffer from chronic kidney disease by 2032
  2. Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222 Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
  3. Isospec Analytics launches biomolecular analysis technology to identify unknown molecules The novel technology optimises the identification process of unknown molecules compared to mass analysis
  4. Building strong foundations for a resilient and planet-friendly future Having recently released its inaugural environmental, social and governance (ESG) report, Dr Kevin Robinson caught up with Gigi Bat-Erdene, Global ESG Program Manager at PCI...
  5. ten23 health and Ypsomed collaborate to commercialise the YpsoDose patch injector The partnership will bring the drug delivery device to the pharmaceutical market quicker, whilst reducing development risks

Upcoming event

Making Pharmaceuticals

23–24 April 2024 | Exhibition | Coventry, UK See all

Related Content

Manufacturing

Bora Pharmaceuticals to acquire US pharma manufacturer Upsher-Smith for $210 Million

Combined, the two manufacturing facilities in Minnesota are capable of commercialising a broad range of dosage forms
Manufacturing

Bora opens facility for Ophthalmic manufacturing

The facility will provide Bora’s customers with access to an extensive range of ophthalmic manufacturing service
Regulatory

Bora and Celltrion team up on oral dosage form drugs

The range of oral dosage form products will be manufactured at Bora’s Zhunan Site, one of the largest pharmaceutical production facilities in Taiwan
Manufacturing

Bringing performance, quality and safety to the pharmaceutical industry

Catching up with a trio of industry outsourcing experts, Dr Kevin Robinson explores the key trends have had the biggest impact on the pharmaceutical’s contract service industry in recent times
Drug Delivery

Bora and TaiRx to manufacture anticancer drug

The novel anticancer drug CVM-1118 is a new small molecule chemical entity being developed by TaiRx
Manufacturing

Leveraging extrusion-spheronisation to fast-forward complex oral solid dose form manufacturing

Converting active pharmaceutical ingredients (APIs) into spheres via extrusion-spheronisation for oral solid dosage (OSD) forms is nothing new. In the right hands, however, with the right capabilities, this process is helping to lead the development and manufacture of todays and tomorrow’s most advanced and patient-centric OSD therapeutics
Manufacturing

Bora Pharmaceuticals establishes biologics CDMO platform

The Taiwan-based international contract development and manufacturing organisation has announced the establishment of Bora Biologics
Subscribe now